Beneficial Collaborations, FDA Authorized Technologies and Divestitures Promoting Quality Healthcare - Research Report on

   Beneficial Collaborations, FDA Authorized Technologies and Divestitures
Promoting Quality Healthcare - Research Report on Agilent, Life Technologies,
                   C. R. Bard, Quest Diagnostics, and Alere

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 4, 2013

NEW YORK, July 4, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Agilent
Technologies Inc. (NYSE: A), Life Technologies Corporation (NASDAQ: LIFE), C.
R. Bard, Inc. (NYSE: BCR), Quest Diagnostics Inc. (NYSE: DGX), and Alere Inc.
(NYSE: ALR). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Agilent Technologies Inc.Research Report

On June 25, 2013, Agilent Technologies Inc. (Agilent) introduced the U5340A
FPGA development kit for high speed digitizers. The kit, which is powered by a
custom Mentor Graphics design engine, enables customers to deploy advanced
real-time signal processing into the FPGAs on board Agilent high-speed
digitizers. According to Agilent, the kit also ensures that the digitizers
deliver high multi-gigasample-per-second performance. "Our close partnership
with Mentor Graphics enabled us to create today's most powerful FPGA
development kit for high-speed digitizers," said Didier Lavanchy, Operation
Manager for Agilent's High-Speed Digitizers Group. "We have used the kit to
design firmware options currently available in our products, and beta
customers have successfully implemented a variety of algorithms. For them and
us, the U5340A has significantly reduced development time and, for the first
time, made possible multi-gigasample-per-second real-time processing." The
Full Research Report on Agilent Technologies Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/075f_A]

--

Life Technologies CorporationResearch Report

On June 26, 2013, Life Technologies Corp. (Life Technologies) announced that
its Applied Biosystems 7500 Fast Dx Real-Time PCR instrument is suitable for
use with the CDC Novel Coronavirus 2012 Real-time RT-PCR Assay, which has
received Emergency Use Authorization for detection in patient specimens of the
novel Middle East Respiratory Syndrome Coronavirus (MERS-CoV). To ensure
proper treatment against the growing threat from MERS-CoV, Life Technologies
stated that it is increasing production of its reagents and shipping them to
labs around the world. "We are working continually with our partners to
improve capabilities, particularly tests that work more quickly and simply on
more people," said Mark Stevenson, President and Chief Operating Officer at
Life Technologies. "Our technology aids public health labs around the globe to
identify threats and develop rapid detection kits." The Company informed that
the test has been authorized by FDA under an Emergency Use Authorization for
use by qualified laboratories, however the CDC Novel Coronavirus 2012 Assay
has neither been FDA cleared nor approved. The Full Research Report on Life
Technologies Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/d9de_LIFE]

--

C. R. Bard, Inc.Research Report

On June 28, 2013, C. R. Bard, Inc. (C. R. Bard) announced that it has entered
into an agreement to sell certain assets of its Electrophysiology (EP)
division to Boston Scientific Corporation for $275 million in cash. Timothy M.
Ring, Chairman and Chief Executive Officer, C. R. Bard, commented, "This
divestiture is consistent with our strategic plan, which is designed to
position our portfolio for accelerated sales growth over time. By exiting the
EP business, we believe we can better direct management's attention and our
capital resources toward pursuing opportunities where we believe we can
achieve sustainable long-term leadership positions and provide attractive
growth and returns to shareholders." The Company anticipates this transaction
to be approximately $0.05 dilutive to its 2013 adjusted EPS. The Full Research
Report on C. R. Bard, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/1010_BCR]

--

Quest Diagnostics Inc.Research Report

On June 26, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced an
agreement with AT&T to provide the Quest Diagnostics Care360 Solution Suite,
including the Care360 electronic health record (EHR) and eprescribing and
laboratory order/results services, through AT&T Healthcare Community Online.
As per the agreement, AT&T will offer, promote and resell the Care360 Solution
Suite through AT&T Healthcare Community Online "Our relationship with AT&T is
an example of how Quest Diagnostics is increasingly collaborating with top
companies to develop new solutions for serving the complex needs of healthcare
providers," said Philip S. Present II, Vice President and General Manager of
Quest Diagnostics' Healthcare Information Technology Service Line. "Through
this agreement, Quest will extend the availability of its Care360 Solution to
a far larger number of large physician practices, hospitals and integrated
delivery networks, including ACOs. AT&T, in turn, will benefit from being able
to offer to its AT&T Healthcare Community Online customers a highly
comprehensive and flexible online EHR solution that meets Meaningful Use
criteria." The Full Research Report on Quest Diagnostics Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/0cb6_DGX]

--

Alere Inc.Research Report

On June 27, 2013, Alere Inc. (Alere) announced that it has partnered with
various Health Departments and Nonprofit Organizations to sponsor HIV testing
events across the US for the National HIV Testing Day (NHTD), which was
observed on the same day. NHTD is an annual observance that promotes testing
as an important strategy to detect, treat and prevent HIV infection. The
campaign was meant to encourage people of all ages to "Take the Test. Take
Control." According to the Centers of Disease Control and Prevention (CDC), in
2010, of all Americans infected with HIV, approximately 18% had not been
diagnosed with the infection. To support the cause, Alere donated free test
kits and made local grants to help raise awareness about HIV testing and
encourage people to get tested for the virus. The Full Research Report on
Alere Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/50a5_ALR]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: Contact: WSReports.com Phone #: +1-310-496-8071
 
Press spacebar to pause and continue. Press esc to stop.